P. Kent Hawryluk

CIK: 0001673991

Transaction Breakdown

Open Market Buys (P)3 (27.3%)

High conviction signal

Open Market Sales (S)1 (9.1%)

Position reduction

Option Exercises (M)2 (18.2%)

Derivative conversions

Awards (A)3 (27.3%)

Compensation grants

Other (G, F, J, C, D, …)2 (18.2%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

MBX

MBX Biosciences, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (11 total)

MBX
MBX Biosciences, Inc.
May 6, 2026
Sale(S)
Direct
607 shares at avg. $29.54$18K
MBX
MBX Biosciences, Inc.
Mar 13, 2026
Purchase(P)
Indirect
18.5K shares at avg. $28.41$526K
MBX
MBX Biosciences, Inc.
Feb 26, 2026
Exercise(M)
Direct
28.8K shares at avg. $16.00$460K
MBX
MBX Biosciences, Inc.
Feb 2, 2026
Award(A)
Direct
35.3K shares-
MBX
MBX Biosciences, Inc.
Oct 24, 2025
Exercise(M)
Direct
182.9K shares at avg. $3.25$594K
MBX
MBX Biosciences, Inc.
Oct 20, 2025
Purchase(P)
Indirect
20K shares at avg. $13.64$273K
MBX
MBX Biosciences, Inc.
Feb 4, 2025
Purchase(P)
Indirect
50K shares at avg. $10.69$535K
MBX
MBX Biosciences, Inc.
Feb 3, 2025
Award(A)
Stock Option (Right to Buy)
Direct
243K shares-
MBX
MBX Biosciences, Inc.
Sep 16, 2024
Conversion(C)
Indirect
115.9K shares-
MBX
MBX Biosciences, Inc.
Sep 16, 2024
Conversion(C)
Direct
283.8K shares-
MBX
MBX Biosciences, Inc.
Sep 12, 2024
Award(A)
Stock Option (Right to Buy)
Direct
120.4K shares-

		Type	Shares	Price		Ownership
May 6, 2026	MBX MBX Biosciences, Inc.	Sale(S)	607	$29.54	$17,931	Direct
Mar 13, 2026	MBX MBX Biosciences, Inc.	Purchase(P)	18,500	$28.41	$525,663	Indirect
Feb 26, 2026	MBX MBX Biosciences, Inc.	Exercise(M)	28,768	$16.00	$460,288	Direct
Feb 2, 2026	MBX MBX Biosciences, Inc.	Award(A)	35,250	-	$0	Direct
Oct 24, 2025	MBX MBX Biosciences, Inc.	Exercise(M)	182,859	$3.25	$594,292	Direct
Oct 20, 2025	MBX MBX Biosciences, Inc.	Purchase(P)	20,000	$13.64	$272,790	Indirect
Feb 4, 2025	MBX MBX Biosciences, Inc.	Purchase(P)	50,000	$10.69	$534,500	Indirect
Feb 3, 2025	MBX MBX Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	243,000	-	-	Direct
Sep 16, 2024	MBX MBX Biosciences, Inc.	Conversion(C)	115,914	-	$0	Indirect
Sep 16, 2024	MBX MBX Biosciences, Inc.	Conversion(C)	283,846	-	$0	Direct
Sep 12, 2024	MBX MBX Biosciences, Inc.	Award(A) Stock Option (Right to Buy)	120,436	-	-	Direct

1-11 of 11 transactions

About Hawryluk P. Kent

Hawryluk P. Kent (SEC CIK 0001673991) files insider reports with the SEC as President & CEO of MBX Biosciences, Inc. (MBX).

Signal8 holds 10 ownership filings by Hawryluk P. Kent (1 Form 3, 9 Form 4), filed between Sep 12, 2024 and May 8, 2026. Those filings report 11 transactions, from Sep 12, 2024 to May 6, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Hawryluk P. Kent's filings is in CARMEL, IN.

Recent filings by Hawryluk P. Kent

May 6, 2026: Open-market sale of MBX shares (Form 4, code S).
Mar 13, 2026: Open-market purchase of MBX shares (Form 4, code P).
Feb 26, 2026: Option exercise of MBX shares (Form 4, code M).
Feb 2, 2026: Grant or award of MBX shares (Form 4, code A).
Oct 24, 2025: Option exercise of MBX shares (Form 4, code M).

Other insiders filing for MBX Biosciences, Inc. (MBX)

Radovich Peter, Director
Azoulay Salomon, Chief Medical Officer
Smither John W, Chief Financial Officer
Hoerter Steven L., President and CEO
Mathers Edward T, Director
Pescovitz Ora H., Director

How to read Form 4 transaction codes